Cargando…

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy

Detalles Bibliográficos
Autores principales:	Rhoades, Ruben, Leong, Ron, Kopenitz, Jason, Thoma, Brandi, McDermott, Lydia, Dovidio, Joseph, Barletti, Shannon, Gong, Jerald Z., Massey, Howard T., McKenzie, Steven E., Rame, J. Eduardo, Al-Rawas, Nawar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053597/ https://www.ncbi.nlm.nih.gov/pubmed/33894473 http://dx.doi.org/10.1016/j.thromres.2021.04.008

Ejemplares similares

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic
por: Parks, Anna L., et al.
Publicado: (2020)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
por: Daughety, Molly M., et al.
Publicado: (2020)

Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients
por: Preti, Paola S., et al.
Publicado: (2021)

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19()
por: Huang, Ching-Tai, et al.
Publicado: (2020)

Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group
por: Ray, Joel G., et al.
Publicado: (2021)

Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis
por: Moll, Matthew, et al.
Publicado: (2021)

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era
por: Qin, Wei, et al.
Publicado: (2021)

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study
Publicado: (2021)

Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
por: Thomas, W., et al.
Publicado: (2020)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Acquired Coagulopathy and Hemorrhage Secondary to Subcutaneous Heparin Prophylaxis
por: Sunseri, Maria, et al.
Publicado: (2018)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
por: Costanzo, Luca, et al.
Publicado: (2020)

Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
por: Honore, Patrick M., et al.
Publicado: (2020)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study
por: Descamps, Richard, et al.
Publicado: (2021)

A Case of COVID-19 Related Coagulopathy Complications and Heparin Resistance
por: Chowdhry, Erum, et al.
Publicado: (2021)

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
por: Xu, Lengnan, et al.
Publicado: (2023)

Thrombosis and coagulopathy in COVID-19 patients rceiving ECMO: A narrative review of current literature
por: Yusuff, Hakeem, et al.
Publicado: (2022)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
por: Streng, Alexander S., et al.
Publicado: (2020)

Relationship between peak anti-Xa levels and calculated creatinine clearance in ICU patients receiving low molecular weight heparin
por: McDonald, E, et al.
Publicado: (2003)

Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?
por: Steinlechner, Barbara, et al.
Publicado: (2021)

Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy
por: Huang, Jia-Jia, et al.
Publicado: (2023)

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes
por: Hornung, Paul, et al.
Publicado: (2020)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation
por: Senzolo, Marco, et al.
Publicado: (2009)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Heparin and Protamine Titration Does Not Improve Haemostasis after Cardiac Surgery: A Prospective Randomized Study
por: Radulovic, Vladimir, et al.
Publicado: (2015)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Running Away to the Circus
por: Wilcox, Lynne S.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_6d005tbk3hu5al4n1alaa2fq6h